FDA sanctions don't kill a business

FDA sanctions may not be the end for a drugmaker. Bloomberg reports that India's Wockhardt Ltd., which was hit with enough violations that the FDA banned products from two of its plants, expects sales to hit $1 billion in 2017, thanks to domestic (as in non-US) sales.

Bloomberg says the firm has become a possible M&A target for peer and neighbor Lupin, Ltd.

“What's attractive about this company, in spite of the import alerts, is its presence in India, the US and Europe,” CIMB securities analyst Prakash Agarwal tells Bloomberg.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.